BioSpace News Archive

3D illustration of an antibody-drug conjugate

Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study, though the deaths have not been linked to patritumab deruxtecan.

September 17, 2024

·

2 min read

·

Tristan Manalac

Hands in black and white dropping a collection of pills on a pink background

Weight loss

Obesity Pill Race Heats Up as Novo, Roche and Terns Share Data

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.

September 17, 2024

·

4 min read

·

Nick Paul Taylor

3D illustration of DNA strand surrounded alien cells, abstract health science illustration

Gene Therapy

Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies

Last month, Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the company races with bluebird bio’s Lyfgenia.

September 17, 2024

·

2 min read

·

Annalee Armstrong

Business

Express Scripts Sues FTC, Demands Withdrawal of ‘False and Misleading’ PBM Report

Pharmacy benefit manager Express Scripts announced Tuesday it has filed a lawsuit in federal court in Missouri against the Federal Trade Commission for its “unfair, biased and erroneous” July report on the industry.

September 17, 2024

·

2 min read

·

Kate Goodwin

Pictured: Infant in the hospital wearing a ventila

RSV

Sanofi, AstraZeneca Get FDA Approval of New Manufacturing Line to Bolster US Supply of RSV Antibody

The newly approved filling line will be able to provide both 50-mg and 100-mg doses of the respiratory syncytial virus antibody Beyfortus to help meet demand ahead of the 2024/2025 RSV season.

September 17, 2024

·

2 min read

·

Tristan Manalac

Pictured: Boehringer Ingelheim sign on a building/

Phase III

Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.

September 17, 2024

·

2 min read

·

Tristan Manalac

GLP-1

GLP-1s Can Potentially Cut Cirrhosis, Related Complications in MASLD: Study

In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor agonists are 14% less likely to progress to cirrhosis.

September 17, 2024

·

2 min read

·

Tristan Manalac

Press Releases

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

September 17, 2024

·

6 min read

Press Releases

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - September 16, 2024